13 April 2022
Visiongain has published a new report Vaccine Contract Manufacturing Market Report 2022-2032: Forecasts by Process (Upstream Process, Downstream Process), by Downstream (Fill & Finish Operations, Analytical & QC Studies, Vaccine Packaging), by Upstream (Mammalian Expression Vaccine, Bacterial Expression Vaccine, Yeast Expression Vaccine, Baculovirus/Insect Expression Vaccine, Other), by Type (Subunit Vaccines, Live Attenuated Vaccines, Conjugate Vaccines, Inactivated Vaccines, Recombinant Vector Vaccines, Other), by Company Size (Small Manufacturers, Mid-sized Manufacturers, Large Manufacturers, Very Large Manufacturers), by Operation (Preclinical, Clinical, Commercial, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.
The global vaccine contract manufacturing market was valued at US$2,378 million in 2021 and is projected to grow at a CAGR of 13.04% during the forecast period 2022-2032.
Unprecedented Vaccine Production Demand
The speed with which the COVID-19 vaccine is being developed, as well as the volume of vaccination demand, is unmatched in contemporary medicine. Stakeholders have had to re-assess their production processes, make big expenditures, repurpose existing facilities, & build intricate supply networks in order to meet this demand. The R&D response to COVID-19 has been remarkable, with numerous vaccines licenced in short time after the virus was discovered. This necessitated a far faster ramp-up of production than is typical in pharmaceutical research, a problem made even more difficult by the worldwide nature of vaccination demand. This goal is three to four times larger than the pre-COVID predicted yearly worldwide demand for all vaccinations (3.5 billion to 5.5 billion doses). Vaccines have been created on a variety of platforms, including some innovative technologies that had had little clinical validation prior to COVID-19 (e.g. mRNA, viral vector). However, due to lack of prior expertise in scaling up manufacturing of these technologies challenged industry participants.
How has COVID-19 had a significant negative impact on the Vaccine Contract Manufacturing Market?
The SARS-CoV-2 pandemic's abrupt outbreak and increasing progression prompted worldwide multilateral organisations and individual private donors to pool their resources to finance research for an effective vaccine against the new coronavirus. From laboratory-based experiments through clinical trials worldwide, a large number of scientific people, technicians, and data managers are engaged. As of November 1, 2021, only 18 vaccinations were indicated as candidates for the WHO emergency use listing and prequalification examination. However, debating the producer of more vaccine candidates and their efficacy would be beyond the scope of this essay, as new vaccinations enter clinical testing every year. They are made accessible in the open market based on proven efficiency and safety. Nonetheless, if the vaccine is accessible on the market for public consumption, it should be disseminated evenly across nations without negotiating its supply with high-income countries, governments, and key stakeholders such as international organisations and pharmaceuticals. The irony of this circumstance is that high-income countries invested in vaccine stock instead of spending that money on rapid capacity building and life-saving medicine delivery via healthcare systems.
How this Report Will Benefit you?
Visiongain’s 565-page report provides 377 tables and 380 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global vaccine contract manufacturing market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Vaccine Contract Manufacturing. Get the financial analysis of the overall market and different segments including type, process, upstream, downstream, company size and capture higher market share. We believe that high opportunity remains in this fast-growing vaccine contract manufacturing market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
What are the Current Market Drivers?
Growth In Infectious Diseases
As a defence against known and unknown infectious disease risks, all nations have established a complex global health system. This healthcare system is made up of a variety of formal and informal networks of organizations that serve a variety of stakeholders, have varying goals, modalities, resources, and accountability, operate at various regional levels (local, national, regional, or global), and span the public, private-for-profit, and private-not-for-profit sectors. The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet. In terms of severity and likelihood, infectious disease risks vary greatly. The infectious diseases also have different effects on morbidity and mortality and a wide range of social and economic ramifications. Increase in incidences of such infectious diseases results into high demand for vaccines and creates business opportunities for vaccines contract manufacturers.
Stakeholder Cooperation Maximizes Manufacturing Capacity
In the atmosphere of the pandemic, vaccine players have put in place a variety of strategies to address manufacturing bottlenecks. Vaccine stakeholders have improved their processes, added capacity through partnerships, and are increasingly focused on local supply chains. To deal with material and equipment limitations, stakeholders with current capabilities have shifted manufacturing capacity to COVID-19 vaccines, temporarily utilizing existing production lines while constructing new lines. Pharma corporations and CDMOs have also made direct investments in new capabilities, for example, Pfizer's $200 million purchase of seven lipid manufacturing machines from Polymum Scientific.
Where are the Market Opportunities?
Advancement In Vaccine Technologies
Vaccines based on living or dead organisms and their components have had much success. On the other hand, traditional techniques have failed to address many of the remaining vaccination issues, such as preventing or treating chronic infections and cancer. To assist the clearance of infected or neoplastic cells, robust cellular immune responses, such as Cytotoxic T lymphocytes (CTLs), may be required in these settings. Furthermore, a narrower focus on important antigens, targeting neoantigens on tumours, may be necessary. To induce these reactions and overcome immunologic tolerance against self-antigens, new techniques for how vaccination antigens are presented and delivered to the immune system will be required (important in cancer). Several potentially enabling technologies such as genomics and proteomics, novel delivery routes, new adjuvants are in the works, and they could significantly impact how vaccines are made now.
The major players operating in the vaccine contract manufacturing market are AbbVie Inc. (AbbVie), Bavarian Nordic A/S, Catalent, Inc., Charles River Laboratories International, Inc., Emergent BioSolutions Inc., Eurofins Scientific SE, FUJIFILM Holdings Corporation, GlaxoSmithKline PLC, Kemwell Biopharma, Lonza Group AG (Lonza), Merck KGaA, Pfizer Inc. (Pfizer), Richter-Helm BioLogics, Samsung Biologics Co Ltd, Sanofi SA, Serum Institute of India, Siegfried Holding AG, Thermo Fisher Scientific Inc., Wacker Biotech B.V, WuXi Biologics Cayman Inc, These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.
• 14th September 2021, Emergent BioSolutions Inc. (NYSE:EBS) and Providence Therapeutics entered into a five-year contract development and manufacturing (CDMO) services agreement spanning Emergent’s integrated capabilities, including development services, bulk drug substance formulation and drug product manufacturing, to support Providence’s COVID-19 messenger RNA (mRNA) vaccine development.
• 2nd November 2021, Lonza, acquired an exosome manufacturing facility located in Lexington, Massachusetts (US) from Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.
31 January 2023
The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.
31 January 2023
The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.
31 January 2023
The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.